ArticleBritish journal of cancer2007
HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
Article in British journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01779050 (A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Archives of pathology & laboratory medicine · 2014Guideline
- Prognostic factors and survival prediction in HER2-positive breast cancer with bone metastases: A retrospective cohort study.Cancer medicine · 2021Article
- EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma.Scientific reports · 2020Article
- Automated detection of the HER2 gene amplification status in Fluorescence in situ hybridization images for the diagnostics of cancer tissues.Scientific reports · 2019Article
- Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer.NPJ breast cancer · 2018Article
- p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer.Oncogene · 2016Article
- Estrogen Receptor and HER2 Status on Disseminated Tumor Cells and Primary Tumor in Patients with Early Breast Cancer.Translational oncology · 2015Article
- Control of MT1-MMP transport by atypical PKC during breast-cancer progression.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Article
- Article
- Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients.Translational oncology · 2012Article
- Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.Journal of cancer research and clinical oncology · 2012Article
- Minimal residual disease and circulating tumor cells in breast cancer.Breast cancer research : BCR · 2011Review
- HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.Virchows Archiv : an international journal of pathology · 2010Article
- Epithelial-to-mesenchymal transitions and circulating tumor cells.Journal of mammary gland biology and neoplasia · 2010Review
- Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis.The oncologist · 2010Article
- Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients.Breast cancer research : BCR · 2009Article
- Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues.Journal of clinical pathology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Discrepancies have been reported between HER2 status in primary breast cancer and micrometastatic cells in bone marrow. The aim of this study was to assess HER2 gene status in micrometastatic cells in bone marrow and corresponding primary tumour. Micrometastatic cells were detected in bone marrow aspirations in a prospective series of 27 breast cancer patients by immunocytochemistry (pancytokeratin antibody). HER2 status of micrometastatic cells was assessed by fluorescence in situ hybridisation (FISH), respectively in 24 out of 27. Primary tumour HER2 status was assessed by immunohistochemistry (CB11 antibody) and by FISH in 20 out of 27 of the cases. HER2 was amplified or overexpressed in five out of 27 (18.5%) primary tumours and in four out of 27 (15%) micrometastatic cells. In two cases, HER2 was overexpressed and amplified in primary tumour, but not in micrometastatic cells, whereas, in one case, HER2 presented a low amplification rate (six copies) in micrometastatic cells not found in the primary tumour. We demonstrated that negative and positive HER2 status remained, in the majority of the cases, stable between the bone marrow micrometastasis and the primary tumour. Therefore, the efficiency of anti-HER2 adjuvant therapy could be evaluated, in a clinical trial, by sequential detection of HER2-positive micrometastatic cells within the bone marrow, before and after treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.